Wednesday, October 7, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 25, 2026

Is It Too Late To Consider Applied Materials (AMAT) After Its 177% One Year Surge?

View original at finance.yahoo.com
Is It Too Late To Consider Applied Materials (AMAT) After Its 177% One Year Surge? Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Applied Materials receives a valuation score of 2 out of 6 on Simply Wall St's valuation checks.

    60% confidence

  • Applied Materials' DCF intrinsic value is estimated at $191.66 per share, meaning the current share price of ~$417.04 is approximately 117.6% above intrinsic value, making it overvalued on this model.

    60% confidence

  • Applied Materials is a key player in the semiconductor equipment space, with a role in supplying tools for chip manufacturing, and has been closely watched as sentiment around chip demand and capital spending shifts.

    60% confidence

  • For a profitable company like Applied Materials, the P/E ratio is a useful way to relate what you are paying per share to the earnings that support that price.

    60% confidence

  • Applied Materials' latest twelve-month free cash flow is approximately $7.0 billion, with analyst and extrapolated estimates projecting FCF reaching about $12.4 billion by 2030.

    60% confidence

Data points we hold from this source

Applied Materials, Inc. · cash7.0 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com
Is It Too Late To Consider Applied Materials (AMAT) After Its 177% One Year Surge? — Source | Via News | ViaNews Market